£2.3M
The seed round was led by SF500, Zentynel and Time Partners to fund technical validation and US expansion.
"80% of CVD-related deaths could be avoided with updated screening practices, like in cancer, where liquid biopsy is already being used to detect the disease earlier and save lives,"
